Alkem Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Show Positive Recalibration

Alkem Laboratories currently trades at a P/E ratio of 26.60, a figure that, while above the broader market average, represents a more reasonable valuation compared to its recent historical levels and some of its more expensive peers. The company’s price-to-book value stands at 4.79, indicating a premium but one that aligns with its robust return metrics and growth prospects. The enterprise value to EBITDA (EV/EBITDA) multiple is 21.99, reflecting a moderate premium relative to sector averages but a discount to some highly valued competitors.

These valuation improvements have contributed to the company’s Mojo Grade upgrade from Sell to Hold as of 4 May 2026, with the current Mojo Score at 50.0. This signals a more balanced risk-reward profile, encouraging investors to reassess Alkem’s position within their portfolios.

Comparative Peer Analysis Highlights Relative Attractiveness

When benchmarked against key pharmaceutical peers, Alkem’s valuation appears increasingly attractive. Lupin, rated as very attractive, trades at a P/E of 21.59 and EV/EBITDA of 14.03, while Zydus Lifesciences, also attractive, has a P/E of 17.49 and EV/EBITDA of 11.59. Conversely, companies such as Mankind Pharma and Laurus Labs remain very expensive, with P/E ratios of 50.05 and 70.85 respectively, and EV/EBITDA multiples well above 29. This contrast underscores Alkem’s improved relative valuation standing within the mid-cap pharmaceutical segment.

Glenmark Pharma, another very attractive peer, trades at a slightly higher P/E of 27.57 but with a significantly lower PEG ratio of 0.03 compared to Alkem’s 2.39, suggesting that while Alkem’s price multiples have become more appealing, its growth expectations remain more modest in comparison.

Financial Performance Supports Valuation Reassessment

Alkem’s return on capital employed (ROCE) stands at a healthy 19.13%, while return on equity (ROE) is 17.61%, both metrics signalling efficient capital utilisation and profitability. These returns justify the premium valuation multiples relative to the broader pharmaceutical sector, which often grapples with pricing pressures and regulatory challenges.

Dividend yield remains modest at 0.95%, reflecting the company’s focus on reinvestment for growth rather than income distribution. This aligns with the pharmaceutical industry’s capital-intensive nature and the need for ongoing research and development expenditure.

Stock Price and Market Performance Context

Alkem’s current share price stands at ₹5,355.20, down slightly by 0.90% from the previous close of ₹5,404.05. The stock has traded within a 52-week range of ₹4,716.75 to ₹5,933.00, indicating a relatively stable price band with moderate volatility. Today’s intraday range was ₹5,321.45 to ₹5,399.95, reflecting typical trading activity.

In terms of returns, Alkem has outperformed the Sensex over multiple time horizons. The stock delivered a 5.85% return over the past year compared to the Sensex’s negative 4.02%, and an impressive 54.11% over three years versus the Sensex’s 25.13%. Over a decade, Alkem’s return of 335.83% significantly outpaces the Sensex’s 207.83%, underscoring its long-term growth credentials.

Valuation Trends and Market Sentiment

The upgrade in valuation grade from fair to attractive reflects a market reassessment of Alkem’s earnings quality and growth outlook. The company’s PEG ratio of 2.39, while higher than some peers, suggests that the market is pricing in steady growth rather than aggressive expansion. This conservative growth expectation may appeal to investors seeking stability amid sector volatility.

Moreover, the mid-cap classification of Alkem Laboratories positions it well to benefit from both growth opportunities and relative resilience compared to smaller, more volatile stocks. The recent Mojo Grade upgrade from Sell to Hold indicates a cautious but positive shift in analyst sentiment, encouraging investors to monitor the stock for further developments.

Investor Takeaway: Balanced Opportunity Amid Sector Dynamics

Alkem Laboratories’ improved valuation metrics and upgraded rating suggest that the stock has become more price attractive relative to its historical levels and peer group. While the P/E and P/BV ratios remain elevated compared to the broader market, they are justified by the company’s strong returns and consistent earnings growth.

Investors should weigh these valuation improvements against the company’s growth prospects and sector risks, including regulatory pressures and competitive intensity. The Hold rating reflects a balanced view, signalling that while the stock is no longer a sell, it may not yet offer the compelling upside of some more aggressively valued peers.

Long-term investors with a focus on quality mid-cap pharmaceutical companies may find Alkem Laboratories a suitable addition, particularly given its outperformance relative to the Sensex over multiple time frames. However, those seeking higher growth or lower valuation multiples might consider exploring alternatives within the sector or across market caps.

Conclusion

Alkem Laboratories Ltd’s recent valuation grade upgrade from fair to attractive, coupled with a Mojo Grade improvement from Sell to Hold, marks a significant shift in market perception. The company’s P/E of 26.60 and P/BV of 4.79 now present a more compelling entry point for investors, supported by solid returns on capital and consistent stock performance. While not without risks, the stock’s relative valuation attractiveness and mid-cap status make it a noteworthy contender in the Pharmaceuticals & Biotechnology sector for investors seeking a balanced risk-return profile.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →